PRLD SEC Filings: 8-K, 10-Q, S-3 & 424B

Financials

TYPE

HEADLINE

FILED AT

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Aug 11, 2026

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

May 12, 2026

10-K

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]

Mar 10, 2026

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Nov 12, 2025

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Aug 14, 2025

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

May 6, 2025

News

TYPE

HEADLINE

FILED AT

8-K

Prelude Therapeutics Receives FDA Clearance of IND Application for PRT13722, First-in-Class Oral KAT6A Selective Degrader

Sep 10, 2026

8-K

Prelude Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update

Aug 11, 2026

8-K

Prelude Therapeutics Incorporated Announces Results of 2026 Annual Meeting of Stockholders

Jun 10, 2026

8-K

Prelude Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update

May 12, 2026

8-K

Prelude Therapeutics Announces Pricing of $90.0 Million Underwritten Offering

Apr 20, 2026

8-K

Prelude Therapeutics Presents Preclinical Data for First-in-Class KAT6A Degrader, PRT13722

Apr 20, 2026

Prospectus

TYPE

HEADLINE

FILED AT

424B5

REGISTERED OFFERING

Apr 20, 2026

424B5

March 2026 ATM | Offering amount: $25,000,000 | Bank: Jefferies LLC

Mar 12, 2026

424B5

SHELF OFFERING | Shares amount: 4,496,744 | Share price: $5.75 | Warrants amount: 12,895,256 | Offering amount: $100,002,710.00

May 19, 2023

424B5

SHELF OFFERING | Share price: $6.51 | Offering amount: $100,000,000.00

May 17, 2023

424B5

ATM | Offering amount: $75,000,000

Mar 15, 2023

424B4

2,500,000 Shares-

Jan 7, 2021

Registrations

TYPE

HEADLINE

FILED AT

S-8

Form S-8 - Securities to be offered to employees in employee benefit plans

Mar 10, 2026

S-3

SHARE RESALE REGISTRATION

Dec 10, 2025

S-8

Form S-8 - Securities to be offered to employees in employee benefit plans

Mar 10, 2025

S-3

SHELF | Offering amount: $400,000,000.00 EFFECTIVE

May 30, 2024

S-3/A

SHELF EFFECTIVE

May 6, 2024

S-3

SHARE RESALE REGISTRATION | Shares amount: 7,936,759 | Share price: $3.38 EFFECTIVE

Feb 15, 2024

Proxies

TYPE

HEADLINE

FILED AT

DEFA14A

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

Apr 29, 2026

DEF 14A

Form DEF 14A - Other definitive proxy statements

Apr 29, 2026

DEFA14A

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

Apr 29, 2025

DEF 14A

Form DEF 14A - Other definitive proxy statements

Apr 29, 2025

PRE 14A

Form PRE 14A - Other preliminary proxy statements

Apr 11, 2025

DEFA14A

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

Apr 26, 2024

Ownerships

TYPE

HEADLINE

FILED AT

SCHEDULE 13G

Soleus Private Equity Fund III, L.P. (Filed by)

Jul 8, 2026

BAKER JULIAN (Reporting)

Jun 10, 2026

Dorton Katina (Reporting)

Jun 10, 2026

Babler Martin (Reporting)

Jun 10, 2026

Bonita David P (Reporting)

Jun 10, 2026

Sandor Victor (Reporting)

Jun 10, 2026

Other

TYPE

HEADLINE

FILED AT

EFFECT

Form EFFECT - Notice of Effectiveness

Dec 17, 2025

CORRESP

Form CORRESP - Correspondence

Dec 15, 2025

EFFECT

Form EFFECT - Notice of Effectiveness

Jun 11, 2024

CORRESP

Form CORRESP - Correspondence

Jun 6, 2024

LETTER

Form UPLOAD - SEC-generated letter

Jun 3, 2024

EFFECT

Form EFFECT - Notice of Effectiveness

May 9, 2024

Prelude Therapeutics Incorporated PRLD · SEC Filings